BioCardia, Inc. (NASDAQ:BCDA - Get Free Report) Director Bill Facteau purchased 13,123 shares of the business's stock in a transaction dated Wednesday, April 23rd. The stock was bought at an average price of $1.91 per share, for a total transaction of $25,064.93. Following the completion of the acquisition, the director now owns 13,123 shares of the company's stock, valued at approximately $25,064.93. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
BioCardia Trading Up 8.5 %
BCDA opened at $1.97 on Friday. The company has a market capitalization of $9.22 million, a price-to-earnings ratio of -0.47 and a beta of 1.21. BioCardia, Inc. has a 12-month low of $1.63 and a 12-month high of $6.15. The business's fifty day simple moving average is $2.27 and its 200-day simple moving average is $2.30.
BioCardia (NASDAQ:BCDA - Get Free Report) last posted its earnings results on Wednesday, March 26th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.62. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.02 million. During the same period last year, the business posted ($8.19) EPS. On average, equities research analysts predict that BioCardia, Inc. will post -3.52 EPS for the current year.
Hedge Funds Weigh In On BioCardia
An institutional investor recently bought a new position in BioCardia stock. CM Management LLC purchased a new stake in BioCardia, Inc. (NASDAQ:BCDA - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 25,000 shares of the company's stock, valued at approximately $54,000. CM Management LLC owned 0.55% of BioCardia at the end of the most recent quarter. 20.57% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, Alliance Global Partners raised shares of BioCardia from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 30th.
Check Out Our Latest Research Report on BCDA
About BioCardia
(
Get Free Report)
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
